CRIS Share Price

Open 1.59 Change Price %
High 1.60 1 Day -0.03 -1.88
Low 1.55 1 Week -0.03 -1.88
Close 1.57 1 Month -0.13 -7.65
Volume 500896 1 Year -1.29 -45.10
52 Week High 3.72
52 Week Low 1.47
CRIS Important Levels
Resistance 2 1.62
Resistance 1 1.60
Pivot 1.57
Support 1 1.54
Support 2 1.52
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
DCTH 0.04 33.33%
RITT 0.04 33.33%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NEXS 0.05 25.00%
PRAN 3.25 24.52%
PGRX 0.06 20.00%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
LIWA 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Curis, Inc. (NASDAQ: CRIS)

CRIS Technical Analysis 5
As on 19th Oct 2017 CRIS Share Price closed @ 1.57 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.32 & Strong Sell for SHORT-TERM with Stoploss of 1.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
CRIS Target for October
1st Target up-side 1.92
2nd Target up-side 2.22
3rd Target up-side 2.52
1st Target down-side 1.06
2nd Target down-side 0.76
3rd Target down-side 0.46
CRIS Other Details
Segment EQ
Market Capital 288233760.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.curis.com
CRIS Address
CRIS
4 Maguire Road
Lexington, MA 02421
United States
Phone: 617-503-6500
Fax: 617-503-6501
CRIS Latest News
Interactive Technical Analysis Chart Curis, Inc. ( CRIS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Curis, Inc.
CRIS Business Profile
Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).